他汀类药物联合曲美他嗪对缺血性心肌病并心衰患者的治疗作用观察

摘要

Objective: To explore effect of statins combined with trimetazidine treatment patients with heart failure and ischemic cardiomyopathy.Methods:110 cases of ICM and heart failure patients From 08-2013 to 12-2014 were randomly divided into experimental group and control group with 55 cases in each group, two groups of patients were given atorvastatin, digitalis , angiotensin enzyme inhibitor, etc, experimental group were treated with trimetazidine (20mg, 3 /d), two groups of patients were consecutively for 3 months.Results:After treatment, the two groups of patients with LVESD, LVEDD signiifcantly decreased, LVEF% signiifcantly increased (P<0.05), the test group LVESD, LVEDD lower than the control group, LVEF% higher than the control group (P<0.05). After treatment, the test group walking distance (396.5 + 40.2) m was signiifcantly higher than that of control group (375.3 + 41.7) m (P<0.05). After treatment in the experimental group, there were 13 patients (45.45%) were signiifcantly higher than those in the control group (23.64%) and the difference was statistically significant (P<0.05).Conclusion:Atorvastatin Combined with trimetazidine in treatment of ischemic cardiomyopathy and heart failure patients can be more signiifcantly improved left ventricular ejection fraction and Improve athletic ability.%目的：观察他汀类药物联合曲美他嗪治疗缺血性心肌病（ICM）并心力衰竭患者疗效。方法：笔者科室2013年8月—2014年12月收治110例ICM并心力衰竭患者，随机数字表法分为试验组和对照组各55例，两组患者均给予阿托伐他汀、洋地黄制剂强心、血管紧张素酶抑制剂（ACEI）、醛固酮拮抗剂、利尿剂、硝酸酯类等常规药物治疗，试验组加用曲美他嗪（20m g，3次/d），两组患者均连续治疗3个月。结果：治疗后两组患者的LVESD、LVEDD显著降低、LVEF%显著提高（P<0.05），试验组的LVESD、LVEDD低于对照组、LVEF%高于对照组（P<0.05）。治疗后试验组的6 min步行距离（396.5±40.2）m显著高于对照组（325.3±41.7） m（P<0.05）。试验组治疗后有25例患者达到显效（45.45%）显著高于对照组的13例（23.64%），差异具有统计学意义（P<0.05）。结论：阿托伐他汀联合曲美他嗪治疗缺血性心肌病并心力衰竭患者能够更加显著的改善患者左室射血分数、提高运动能力。